Vasomune Therapeutics to Present on Pegevongitide Therapeutic Capability at the 2026 NATO NSPA CBRN

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions Saved Articles My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Vasomune Therapeutics to Present on Pegevongitide Therapeutic Capability at the 2026 NATO NSPA CBRNAuthor of the article: You can save this article by registering for free here. Or sign-in if you have an account.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountDr. Brian Jahns will present a therapeutics capability update of Pegevongitide (AV-001), Vasomune’s dual-use drug candidate targeting vascular leak, an underlying pathology across casualty careTORONTO — Vasomune Therapeutics, Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing therapies that target vascular leak, today announced that the company has been invited to present at the 2026 NATO Support and Procurement Agency (NSPA) for chemical, biological, radiological, and nuclear (CBRN) threats, taking place September 28-29, 2026, at its headquarters in Capellen, Luxembourg.The NATO NSPA CBRN Conference is a premier international forum focused on advancing medical countermeasures and technologies that enhance preparedness for CBRN threats. Participation provides an opportunity to engage with defence, government, and scientific leaders on innovative dual-use medical technologies that can improve both military personnel survivability and civilian health emergency preparedness.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againVascular leak, or the breakdown of the endothelial barrier that lines blood vessels, allows fluid and proteins to quickly escape circulation and leak into surrounding tissues, often causing edema and end-organ failure. Vascular leak is a common and deadly underlying pathology seen in conditions of concern to defence and public health authorities such as acute respiratory distress syndrome (ARDS), hemorrhagic shock, trauma and shock following severe burns. Pegevongitide (AV-001), Vasomune’s first-in-class, PEGylated peptide that activates the Tie2 receptor and blocks vascular leak at the source by stabilizing the vascular endothelium. Vasomune is advancing the clinical development of Pegevongitide, in a co-development program with AnGes, Inc.“Vascular leak is a common theme that links many types of injuries, from blast trauma and burn injury to infection-driven ARDS,” said Dr. Brian Jahns, Chief Executive Officer at Vasomune. “We are pleased to have the opportunity to update NATO NSPA CBRN about our work to block vascular leak.”About Vasomune Therapeutics, Inc.Vasomune Therapeutics, Inc., is a private clinical-stage biopharmaceutical company developing the next generation of medicines to boost the body’s ability to defend against vascular leak. Pegevongitide (AV-001), discovered and researched at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, is a novel investigational medicine being developed by Vasomune Therapeutics under a co-development agreement with AnGes, Inc. [TYO: 4563] to target vascular leak. Pegevongitide is a first-in-class, PEGylated peptide that activates the Tie2 receptor, a transmembrane protein highly expressed on the surface of endothelial cells in the vasculature, thereby blocking vascular leak. Vascular leak, or the breakdown of the endothelial barrier that lines blood vessels, allows fluid and proteins to quickly escape circulation and leak into surrounding tissues, often causing edema and end-organ failure. Vascular leak is a common and deadly underlying pathology seen in a broad range of disease states including bacterial and viral pneumonia, acute respiratory distress syndrome (ARDS), hemorrhagic shock, trauma and shock following severe burns. Vasomune’s corporate headquarters and laboratories are located in Toronto, Canada, with U.S. offices in Raleigh, NC. For more information, please visit www.vasomune.com.AnGes, Inc., a biopharmaceutical company founded in December 1999, focuses on the development of gene-based medicines. The company’s flagship development product and genetic drug, HGF gene therapy products, received Breakthrough Therapy designation from the FDA in 2024. AnGes is currently working on the development of a Tie2 tyrosine kinase receptor agonist for the treatment of vascular leak and an NF-κB decoy oligonucleotide for chronic discogenic lumbar back pain. Furthermore, AnGes acquired EmendoBio in December 2020 to expand its capabilities in genome-editing technologies. For more information, visit https://www.anges.co.jp/en/.View source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.